drug · antibody

EBGLYSS

updated 5mo ago

by $LLY ELI LILLY & Co🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 3

Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for atopic eczema and eczematoid dermatitis and 5 investigational indications.

targets

Interleukin-13

all catalysts(0)

nothing on the calendar yet

News(4)

Pfizer’s eczema drug clears skin in mid-stage trial
Detailed results are competitive with Dupixent and Ebglyss, but the drug lacks differentiation amid an increasingly competitive landscape, one analyst argued.
biopharma_dive · 2d ago
6 immunology targets to sustain a mammoth I&I market
Johnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…
biospace · 6d ago
North Immunology goes public via reverse merger as eczema drug heads toward clinic
North Immunology has decided its path to taking an atopic dermatitis drug into the clinic involves going public via a reverse merger.
fiercebiotech · 17d ago
Chasing Dupixent, a biotech aims to make better antibody drugs for eczema
Infinimmune, a California startup, is developing treatments it claims might last longer and be more effective than existing atopic dermatitis medications.
biopharma_dive · 1mo ago

brand

EBGLYSS

trade names

Ebglyss

generic

LEBRIKIZUMAB-LBKZ

MOA

12.1 Mechanism of Action Lebrikizumab-lbkz is an IgG4 monoclonal antibody that binds with high affinity and slow off-rate to interleukin (IL)-13 and allows IL-13 to bind to IL-13Rα1 but inhibits human IL-13 signaling through the IL-4Rα/IL-13Rα1 receptor complex. IL-13 is a naturally occurring cytokine that is involved in Type 2 inflammation, which is an important component in the pathogenesis of atopic dermatitis. Lebrikizumab-lbkz inhibits IL-13-induced responses including the release of proinflammatory cytokines, chemokines and IgE. Lebrikizumab-lbkz-bound IL-13 can still bind IL-13Rα2 allowing subsequent internalization and natural clearance of IL-13.

indication

1 INDICATIONS AND USAGE EBGLYSS is indicated for the treatment of adults and pediatric patients 12 years of age and older who weigh at least 40 kg with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. EBGLYSS can be used with or without topical corticosteroids. EBGLYSS ® is an interleukin-13 antagonist indicated for the treatment of adults and pediatric patients 12 years of age and older who weigh at least 40 kg with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. EBGLYSS can be used with or without topical corticosteroids. ( 1 )

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 4h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

News(4)

Pfizer’s eczema drug clears skin in mid-stage trial

Detailed results are competitive with Dupixent and Ebglyss, but the drug lacks differentiation amid an increasingly competitive landscape, one analyst argued.

biopharma_dive · 2d ago

6 immunology targets to sustain a mammoth I&I market

Johnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…

biospace · 6d ago

North Immunology goes public via reverse merger as eczema drug heads toward clinic

North Immunology has decided its path to taking an atopic dermatitis drug into the clinic involves going public via a reverse merger.

fiercebiotech · 17d ago

Chasing Dupixent, a biotech aims to make better antibody drugs for eczema

Infinimmune, a California startup, is developing treatments it claims might last longer and be more effective than existing atopic dermatitis medications.

biopharma_dive · 1mo ago

EBGLYSS

🐶 often sniffed alongside

targets

all catalysts(0)

News(4)

Report a data issue

comments(0)

EBGLYSS

🐶 often sniffed alongside

targets

all catalysts(0)

News(4)

Report a data issue

comments(0)